AgingResearch.NewsJoin free

Congruence Therapeutics

CompanyCanada

Wikidata

Congruence Therapeutics develops 3 assets, the furthest in phase 1 (CGX-926 in genetic obesity due to MC4R deficiency). Mostly small molecule acting on MC4R, SERPINA1 and GBA1; based in Canada.

3
Assets
Furthest stage
Phase 1
Raised
US$132m + CA$52m
0
Trials
0
Signals

Pipeline

3

  • CGX-926

    Corrects mutated MC4R folding and trafficking, restoring receptor function.

    Phase 1, Small molecule, MC4R, genetic obesity due to MC4R deficiency

  • CGX-195

    Stabilizes mutant AAT, reduces polymerization, and increases secretion of functional AAT.

    Preclinical, Small molecule, SERPINA1, alpha-1 antitrypsin deficiency

  • CO-1

    Activates lysosomal glucocerebrosidase activity.

    Preclinical, Small molecule, GBA1, gba-driven Parkinson’s disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Funding rounds and grants5
  • People20
  • Similar companies6

Intelligence